Home - SoftOx Solutions

ABOUT US

A pharmaceutical company

SoftOx Solutions AS (SoftOx, listed at Euronext Growth Oslo) is a clinical-stage pharmaceutical company based in Oslo, Norway. We have developed a non-toxic and highly efficient antimicrobial technology designed to address some of the world’s greatest health challenges, including:

Targeting airway infections with endogenous molecule

The SoftOx technology stabilizes an endogenous pan-antimicrobial molecule (HOCl) thereby enhancing one of the immune system’s ways of eradicating pathogens in the airways.

Alleviating antimicrobial resistance (AMR) development

As HOCl’s mode of action is unspecific and metabolic independent, no resistance develops when using SoftOx technology. According to the World Health Organization, AMR is a major threat to global health. New forms of resistance are emerging and can spread with remarkable speed between continents. Therefore, the SoftOx technology is likely highly important to counteract this detrimental development.

VAP and chronic infections

SoftOx Inhalation Solution (SIS) is effective against pathogens causing VAP as well as other airway infections/pneumonia. With inhaled administration of the nebulized SIS, the treatment will be local, tolerable and is expected to be highly effective.

Spread of viruses

Deadly viral outbreaks are expected in the future. There remains an unmet need for effective and well-tolerated virucidal solutions to aid infection prevention and control. SoftOx Inhalation Solution (SIS) has a strong virucidal capacity.

OUR VISION

New ways of eradicating infections

Our vision seemed almost unreachable when SoftOx began work on its formulations 10 years ago. It took plenty of hard work, a strong belief in our research, and a stubbornness to overcome uncertainties, setbacks, and other challenges, and get to where we are today. Thanks to the dedication and commitment of our team, and to the core values we all share, SoftOx is currently in a prime position.

As SoftOx develops into a well-known brand, we will learn to navigate various obstacles. It is therefore important to emphasize that our long-term goals are now within reach, and our ongoing research and development have resulted in greater confidence and optimism than ever before.

Charles Alexandre de Calonne once said: “Nothing is impossible, the impossible just takes a little longer”. This statement corresponds well with our dedication to developing solutions serving human health.

Laboratory beaker in analyst's hand in plastic glove.

WE ARE COLLABORATING WITH

Leading Research Institutions & Organisations

After years of research and product development

In collaboration With leading Nordic research institutes

SoftOx has developed a non-toxic and highly effective antimicrobial technology, which eradicates and prevents biofilm infections and is fully virucidal.

SoftOx is all about Technology

The unique SoftOx technology, developed in close collaboration with expert scientists and clinicians from the universities in Skåne County and the University of Copenhagen, is based on a combination of naturally occurring chemicals that harbour broad antimicrobial effects without inducing resistance. There is documentation to confirm that this technology has a strong antimicrobial effect against all bacteria (including MRSA), fungi, and viruses tested. Pre-clinical and clinical trials indicate that SoftOx technology is well tolerated. Given its favorable benefit-risk profile, SoftOx technology aims to raise the standards for disinfectants and wound care products.

Developed With Top Ranked Scientists

Aiming to Solve Major Health Challenges

Strong antimicrobial effects on
bacteria, viruses, fungi and spores

*Influenza virus